Decoy Therapeutics

Decoy Therapeutics is a preclinical stage biotech company building a pandemic preparedness drug development platform using AI design of peptide ‘decoys’ that directly interfere with viral replication machinery.

www.decoytx.com

Decoy Therapeutics

www.decoytx.com

HQRemote

Team Size13

Open JobsUnknown

Total Funding$250K

Latest Fundraise5 years ago

TL;DR

Stage: Preclinical

Platform: AI/ML-enabled IMP3ACT™ for peptide-conjugate therapeutics

Therapeutic focus: Broad-acting antivirals (pan-coronavirus, multi-respiratory) and GPCR-targeted peptide–drug conjugates

Founded: 2020

Notable investor/supporter: Massachusetts Life Sciences Center

Company Overview

Problem Domain

Antiviral therapeutics and peptide–drug conjugates for oncology

Founded

2020

Industry

Biotechnology

Tech Stack

AI/ML-driven discovery (IMP3ACT™)

Peptide-conjugate therapeutics

Scalable peptide synthesis/manufacturing

Funding Track Record

Convertible Note- 2021-04-22

250000.00 USD

Investor Signal

“Massachusetts Life Sciences Center; affiliations with Creative Destruction Lab and University of Toronto; merged/acquired by Salarius Pharmaceuticals (announced January 13, 2025)”

Founders

What we do

TL;DR

Company Overview

Funding Track Record

Founders

What we do

Decoy Therapeutics

www.decoytx.com

Decoy Therapeutics

www.decoytx.com

HQRemote

Team Size13

Open JobsUnknown

Total Funding$250K

Latest Fundraise5 years ago

TL;DR

Stage: Preclinical

Platform: AI/ML-enabled IMP3ACT™ for peptide-conjugate therapeutics

Therapeutic focus: Broad-acting antivirals (pan-coronavirus, multi-respiratory) and GPCR-targeted peptide–drug conjugates

Founded: 2020

Notable investor/supporter: Massachusetts Life Sciences Center

Company Overview

Problem Domain

Antiviral therapeutics and peptide–drug conjugates for oncology

Founded

2020

Industry

Biotechnology

Tech Stack

AI/ML-driven discovery (IMP3ACT™)

Peptide-conjugate therapeutics

Scalable peptide synthesis/manufacturing

Funding Track Record

Convertible Note- 2021-04-22

250000.00 USD

Investor Signal

“Massachusetts Life Sciences Center; affiliations with Creative Destruction Lab and University of Toronto; merged/acquired by Salarius Pharmaceuticals (announced January 13, 2025)”

Founders

What we do

Join the Team

Teeming tracks opportunities at over 24,000 AI startups, then works with you to find (and land) the one you'll love.

Product Designer

ContractUtrecht, NL

Contract • Utrecht, NL

Backend Developer

Full-timeAustin, US

Full-time • Austin, US

Frontend Developer

ContractAustin, US

Contract • Austin, US

Product Designer

Part-timeJerusalem

Part-time • Jerusalem

Software Engineer

InternshipBelgrade, RS

Internship • Belgrade, RS

Machine Learning Engineer

InternshipManchester, GB

Internship • Manchester, GB